

# Daniil Stroyakovskiy

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8125598/daniil-stroyakovskiy-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

7,994  
citations

19  
h-index

31  
g-index

31  
ext. papers

10,704  
ext. citations

18.2  
avg, IF

5.28  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 31 | Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101601  | 2.2  | 10        |
| 30 | Impact of preoperative targeted therapy duration on survival in patients with distant primary site and Stage III-IV non-small cell lung cancer in the presence of mutations in the EGFR gene. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , <b>2022</b> , 11, 28                                | 0.2  |           |
| 29 | Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , <b>2021</b> , 158, 156-168                     | 7.5  | 5         |
| 28 | IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , <b>2021</b> ,   | 8.9  | 17        |
| 27 | Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). <i>BioDrugs</i> , <b>2021</b> , 35, 429-444  | 7.9  | 5         |
| 26 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 655-664                                     | 21.7 | 9         |
| 25 | Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice. <i>Journal of Modern Oncology</i> , <b>2021</b> , 23, 68-76  | 0.3  |           |
| 24 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 643-654                                   | 21.7 | 58        |
| 23 | 5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , <b>2021</b> ,  | 12.9 | 10        |
| 22 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1909-1924  | 8.9  | 37        |
| 21 | Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 398, 131-142  | 4.0  | 27        |
| 20 | Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.. <i>JAMA Oncology</i> , <b>2021</b> ,  | 13.4 | 7         |
| 19 | Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra <sup>®</sup> , BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON. <i>Journal of Modern Oncology</i> , <b>2021</b> , 23, 695-702 | 0.3  |           |
| 18 | Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2020</b> , 395, 1835-1844                | 4.0  | 204       |
| 17 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1351-1360  | 8.9  | 160       |
| 16 | Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2206-2216  | 2.2  | 78        |
| 15 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 626-636   | 59.2 | 489       |

|    |   |      |      |
|----|---|------|------|
| 14 | Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, e190339   | 13.4 | 34   |
| 13 | Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 387-401  | 35.1 | 398  |
| 12 | Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF mutation-positive melanoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 777-784   | 8.7  | 14   |
| 11 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2288-2301  | 59.2 | 1695 |
| 10 | IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA9000-LBA9000  | 2.2  | 136  |
| 9  | Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 115-126  | 21.7 | 203  |
| 8  | HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. <i>European Journal of Cancer</i> , <b>2016</b> , 62, 62-75                                 | 7.5  | 55   |
| 7  | Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1248-60  | 21.7 | 590  |
| 6  | Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 833-40  | 7.5  | 60   |
| 5  | coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 61                            | 8.5  | 7    |
| 4  | Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1389-98 | 21.7 | 162  |
| 3  | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , <b>2015</b> , 386, 444-51  | 40   | 926  |
| 2  | Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1867-76  | 59.2 | 1403 |
| 1  | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1877-88  | 59.2 | 1195 |